Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus

Journal of Clinical and Translational Endocrinology

Volumn 1, Issue 2, 2014, Pages 54-60

  Qiu, Rong ^a   Capuano, George ^a   Meininger, Gary ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Canagliflozin; Metformin; Sodium glucose co transporter 2 (SGLT2) inhibitor; Twice daily (BID); Type 2 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CANAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FUNGAL GENITAL INFECTION; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; OSMOTIC DIURESIS; PHASE 2 CLINICAL TRIAL; POLLAKISURIA; POSITIONAL DIZZINESS; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; URINARY TRACT INFECTION; WEIGHT CHANGE; WEIGHT REDUCTION;

EID: 84903156025     PISSN: None     EISSN: 22146237     Source Type: Journal    
DOI: 10.1016/j.jcte.2014.04.001     Document Type: Article

References (17)

1. M.N. Cook, C.J. Girman, P.P. Stein, and C.M. Alexander Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care Diabet Med 24 2007 350 358
2. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, and M. Nauck et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379
3. J.B. Brown, C. Conner, and G.A. Nichols Secondary failure of metformin monotherapy in clinical practice Diabetes Care 33 2010 501 506
4. GLUCOPHAGE® XR (metformin hydrochloride) extended-release tablets [package insert] 2009 Bristol-Myers Squibb Company Princeton, NJ
5. Z.T. Bloomgarden, R. Dodis, C.M. Viscoli, E.S. Holmboe, and S.E. Inzucchi Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis Diabetes Care 29 2006 2137 2139
6. INVOKANA™ (canagliflozin) tablets, for oral use [package insert] 2013 Janssen Pharmaceuticals Titusville, NJ
7. K. Stenlöf, W.T. Cefalu, K.-A. Kim, M. Alba, K. Usiskin, and C. Tong et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise Diabetes Obes Metab 15 2013 372 382
8. J.F. Yale, G. Bakris, B. Cariou, D. Yue, E. David-Neto, and L. Xi et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease Diabetes Obes Metab 15 2013 463 473
9. W.T. Cefalu, L.A. Leiter, K.-H. Yoon, P. Arias, L. Niskanen, and J. Xie et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial Lancet 382 2013 941 950
10. G. Schernthaner, J.L. Gross, J. Rosenstock, M. Guarisco, M. Fu, and J. Yee et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial Diabetes Care 36 2013 2508 2515
11. B. Bode, K. Stenlöf, D. Sullivan, A. Fung, and K. Usiskin Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial Hosp Pract 41 2013 72 84
12. F. Lavalle-González, A. Januszewicz, J. Davidson, C. Tong, R. Qiu, and W. Canovatchel et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial Diabetologia 56 2013 2582 2592
13. J.P. Wilding, G. Charpentier, P. Hollander, G. Gonzalez-Galvez, C. Mathieu, and F. Vercruysse et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial Int J Clin Pract 67 2013 1267 1282
14. J. Rosenstock, N. Aggarwal, D. Polidori, Y. Zhao, D. Arbit, and K. Usiskin et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes Diabetes Care 35 2012 1232 1238
15. K. Stenlöf, W.T. Cefalu, K.A. Kim, E. Jodar, M. Alba, and R. Edwards et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study Curr Med Res Opin 30 2014 163 175
16. S. Sha, D. Devineni, A. Ghosh, D. Polidori, S. Chien, and D. Wexler et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects Diabetes Obes Metab 13 2011 669 672
17. T. Sarich, D. Devineni, A. Ghosh, D. Wexler, K. Shalayda, and J. Blake et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2 (SGLT2), increases 24-h urinary glucose excretion and decreases body weight in obese subjects Diabetes 2010 59 Abstract 567-P